September 9, 2021 7:33pm

The oversold were recognized and popped a bit

Pre-open indications: 5 HITs and 1 MISS

My comments try to distinguish the temporary from real pricing digression or progress with a 360-degree view.

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

The Dow closed DOWN -151.69 points (-0.43%); the S&P closed DOWN -20.79 points (-0.46%) while the Nasdaq closed DOWN -38.38 points (-0.46%)

 

Henry’omics:

Market gains were driven to the downside as investors remained cautious as they try to discern what’s next to happen with the delta variant, the economic reopening and the Fed.

The market still hasn’t regained its footing since the August jobs report released Friday came in much worse than expected. <CNBC>

Despite recent losses, the major benchmarks are still up big for the year and within striking distances of their all-time highs. The S&P 500, up 20% in 2021, is less than 1.2% from its all-time high. The Dow, up 14% this year, is about 2% from a record.

 

Data Docket: Helping sentiment was a better-than-expected weekly reading on jobless claims. Initial jobless claims came in 310,000, which was below expectations of 335,000 claims. This marked another fresh low for the pandemic era.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Thursday opened positive at 20/13, 1 flat and 1 acquired, stayed positive at the mid-day to 24/10 and 1 acquired, closing positive 20/13, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “more volatility and some bounces” … https://www.regmedinvestors.com/articles/12084

 

The Biostage (BSTG) Chronicles: “Facts from filed 10-Q” … still a few to report … https://www.regmedinvestors.com/articles/12055

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23

 

Key Metrics:

  • Sector volume was LOW with 5 of the 20-upside having higher than the 3-month average volume with very LOW volume of 2 of 13-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 20-upside were +0.19% (BLFS) to +19.88% (BSTG) while the 13-downside -0.29% (FATE) to -6.30% (MESO);

 

The Biostage (BSTG) Chronicles: Is up to its usual “pump/promote” Thursday traded up +$0.66 to $3.98 with 6,0622 shares traded after Wednesday traded +$0.57 with 7,833 shares traded, Tuesday closed down -$0.75 to $2.75 with 6,705 shares traded following Monday’s holiday

The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?https://www.regmedinvestors.com/articles/12087

  • Today is just another fact, how the share trades with the “push/promote” - another typical example,
  • WHAT is BSTG’s value proposition, after all the share price “pumping”?

 

Pre-open Indications: 5 HITs <SELL:  ReNeuron (RENE.L -$4.00); SELL into profit: Intellia Therapeutics (NTLA +$0.92), CRISPR Therapeutics (CRSP +$2.20), Editas Medicine (EDIT +$0.13), Cellectis SA (CLLS +$0.55)> 1 MISS <SELL: Biostage (BSTG +$0.66)> 

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Alnylam Pharmaceuticals (ALNY), Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), uniQure NV (QURE), Cellectis SA (CLLS) to name 5 of the 20 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), Sage Therapeutics (SAGE), Ultragenyx (RARE), Ionis Pharmaceuticals (IONS), Mesoblast (MESO) to name 2 of the 13 declining of the 35 covered

 

Thursday (10 of 20)

  • Alnylam Pharmaceuticals (ALNY +$3.29 after Wednesday’s -$1.96 and Tuesday’s -$9.19);
  • CRISPR Therapeutics (CRSP +$2.20 after Wednesday’s -$1.25 and Tuesday’s -$1.45);
  • Intellia Therapeutics (NTLA +$0.92 after Wednesday’s -$3.36 and Tuesday’s -$13.53);
  • uniQure NV (QURE +$0.78);
  • Biostage (BSTG +$0.66 after Wednesday’s +$0.57 and Tuesday’s -$0.75);
  • Cellectis SA (CLLS +$0.55 after Wednesday’s -$0.67);
  • bluebird bio (BLUE +$0.33 after Wednesday’s +$0.50 and Tuesday’s -$0.63);
  • Regenxbio (RGNX +$0.16 after Wednesday’s -$0.86 and Tuesday’s -$0.64);
  • Sangamo therapeutics (SGMO +$0.13);
  • Editas Medicine (EDIT +$0.13 after Wednesday’s -$2.41 and Tuesday’s -$1.52);

Thursday’s (10 of 13) decliners:

  • ReNeuron (RENE.L -4.00 after Wednesday’s -$1.50)
  • MiMedx (MDXG -$0.48 after Wednesday’s +$0.15 and Tuesday’s +$0.12);
  • Sage therapeutics (SAGE -$1.08);
  • mesoblast MESO -$0.41);
  • AxoGen (AXGN -$0.40 after Wednesday’s +$0.01 and Tuesday’s +$0.27);
  • Chinook Therapeutics (KDNY -$0.03 after Tuesday’s +$0.52);
  • Ionis Pharmaceuticals (IONS -0.71 after Wednesday’s -$0.58 and Tuesday’s -$1.97);
  • Pluristem (PSTI -$0.04);
  • Ultragenyx (RARE -$1.06 after Wednesday’s +$0.32 and Tuesday’s -$0.42);
  • Bellicum Pharmaceuticals (BLCM -$0.03);

Closing flat –1 – Solid Biosciences (SLDB) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed up +0.12% and XBI closed up +0.39%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +0.84 points or +4.68% at 18.80

Upside volume:

  • Thursday: 5 out of the 20-upside had higher than the 3-month average volume;

Downside volume:

  • Thursday: 2 out of the 13-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Thursday’s percentage (%) of the 20-upside were +0.19% (BLFS) to +19.88% (BSTG) while the 13-downside -0.29% (FATE) to -6.30% (MESO);

 

September, the third month of Q3/21:

  • Thursday closed positive with 20 advancers, 13 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: The month of September begins with the cell and gene therapy sector up for two (2) sessions and down for three (3) sessions, a holiday and a spurt to the upside.

I am still waiting for clinical data and foresee a bumpy September-October timeframe.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

Q2 reporting season has essentially run its course; although a few remain with my questions of WHY so late …?

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.